The lancet oncology
-
The lancet oncology · Sep 2014
Randomized Controlled Trial Multicenter Study Comparative StudyIntegrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer.
The management of depression in patients with poor prognosis cancers, such as lung cancer, creates specific challenges. We aimed to assess the efficacy of an integrated treatment programme for major depression in patients with lung cancer compared with usual care. ⋯ Cancer Research UK and Chief Scientist Office of the Scottish Government.
-
The lancet oncology · Sep 2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL. ⋯ Pharmacyclics Inc, Cancer Prevention and Research Institute of Texas, Leukemia and Lymphoma Society, National Cancer Institute, MD Anderson Cancer Center.
-
The lancet oncology · Sep 2014
Randomized Controlled Trial Comparative StudyFlexible sigmoidoscopy screening for colorectal cancer.